AlphaMeld Corporation
Madan Anant is an accomplished professional in the fields of drug discovery and biomarker research, currently serving as Vice President of Discovery Biology and Executive Director of Drug Discovery at InveniAI since October 2021. Anant has held various senior roles, including Senior Director of Alliances at InveniAI Corporation and Scientific & Business Development Consultant at Recombinant Technologies. With a robust consulting background for several biotechnology firms, Anant has successfully led projects involving novel biomarker detection platforms, performed scientific due diligence, and managed collaborations across multiple therapeutic areas. Anant's extensive experience spans over two decades, featuring previous positions at Clinical Data, Inc., Genaissance Pharmaceuticals, Gene Logic, and CuraGen Corporation. Anant earned a Ph.D. in Life Sciences from the Indian Institute of Science, further establishing a strong foundation for expertise in scientific and business development within the life sciences sector.
This person is not in any offices
AlphaMeld Corporation
Headquartered in Guilford, CT, AlphaMeld® Corporation (a wholly owned subsidiary of InveniAI LLC) stands as a global frontrunner in the application of AI, machine learning, and generative AI tools, catalyzing innovation throughout drug discovery and development. With a mission to identify and expedite transformative therapies for diseases with unmet medical needs, the company utilizes its cutting-edge AlphaMeld platform to extract valuable insights from petabytes of diverse data sets, propelling the creation of groundbreaking drug programs. The company's pioneering approach is underscored by successful collaborations with industry leaders and drug spinouts, solidifying its position as a trailblazer in the realm of AI-driven drug discovery. About The AlphaMeld® Platform The AlphaMeld platform employs a comprehensive approach to generate testable hypotheses, considering factors such as the ideal mode of pharmacotherapy, disease severity, gene ontology, disease pathways, proteinopathies, standard of care, emerging innovation, and enabling technologies. This is done while factoring in medical, scientific, strategic, and commercial considerations.